The use of 2 different podocyte markers (p57+ and WT1+) found preservation of podocyte number by sparsentan and less potently by losartan (Figure 6, A and B) within only a relatively short (6 weeks) treatment compared with the 1.5 years of age and ongoing FSGS pathology development. Here, WT1 is linked to focal segmental glomerulosclerosis.